glaxo-mohan.blogspot.com
GlaxoSmithKlineMy thoughts on GlaxoSmithKline as an investment
http://glaxo-mohan.blogspot.com/
My thoughts on GlaxoSmithKline as an investment
http://glaxo-mohan.blogspot.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Thursday
LOAD TIME
0.4 seconds
PAGES IN
THIS WEBSITE
5
SSL
EXTERNAL LINKS
35
SITE IP
216.58.194.161
LOAD TIME
0.372 sec
SCORE
6.2
GlaxoSmithKline | glaxo-mohan.blogspot.com Reviews
https://glaxo-mohan.blogspot.com
My thoughts on GlaxoSmithKline as an investment
glaxo-mohan.blogspot.com
GlaxoSmithKline: Positives
http://glaxo-mohan.blogspot.com/2007/11/positives.html
My thoughts on GlaxoSmithKline as an investment. 1 Largest pharmaceuticals company in UK. 2 Second largest pharmaceutical company in the world. 3 S&P rating AA/Stable/A-1 (at 12-10-07). 4 Risks spread over diversified portfolio of products in nine therapeutic areas. 6 Relatively less vulnerable to economic cycles. Potential for growth in sales. 1 Gained market share relative to Pfizer (largest pharmaceutical company) in 2005. 4 Smaller companies that develop new products would need involvement (co-develo...
GlaxoSmithKline: November 2007
http://glaxo-mohan.blogspot.com/2007_11_01_archive.html
My thoughts on GlaxoSmithKline as an investment. GSK is a good company operating in an industry whose fundamentals have deteriorated since the high growth era that ended a few years ago. To quote Warren Buffet: "When a management with a reputation for brilliance tackles a business with a reputation for poor fundamental economics, it is the reputation of the business that remains intact.". 1 Largest pharmaceuticals company in UK. 2 Second largest pharmaceutical company in the world. 2 Global pharmaceutica...
GlaxoSmithKline: Negatives
http://glaxo-mohan.blogspot.com/2007/11/negatives.html
My thoughts on GlaxoSmithKline as an investment. Litigation risks. One bad outcome can wipe out several years of profits. Numerous litigations at all times:. 1 Product liablility, e.g. Paxi/Seroxat, Avandia, etc litigation, particularly in the USA, is inherently unpredictable and excessive verdicts that are not justified by the evidence can occur. Executives’ integrity suspect. (But NEDs seem to be addressing this – see “Good non-executive directors” in "positives". 3 False Vitamin C claim re Ribena.
GlaxoSmithKline: Conclusion
http://glaxo-mohan.blogspot.com/2007/11/conclusion.html
My thoughts on GlaxoSmithKline as an investment. GSK is a good company operating in an industry whose fundamentals have deteriorated since the high growth era that ended a few years ago. To quote Warren Buffet: "When a management with a reputation for brilliance tackles a business with a reputation for poor fundamental economics, it is the reputation of the business that remains intact.". 3 February 2010 at 22:24. 失意人前，勿談得意事；得意人前，勿談失意事。 . 1 March 2010 at 07:52. 看看blog放鬆一下，工作累死了. . 19 March 2010 at 03:50.
GlaxoSmithKline: Unknowns
http://glaxo-mohan.blogspot.com/2007/11/unknowns.html
My thoughts on GlaxoSmithKline as an investment. GSK spends about £3.5 bn per year on R&D. Much of it comes to nothing. Like all big pharmaceutical companies, GSK hope that a small portion of the spending will result in a few marketable drugs that will generate sufficient profits to give a reasonable overall return to shareholders commensurate with the risk they bear. But neither GSK nor anybody else knows as to which portion of the spend will be successful. Forex rates movements (specially $).
TOTAL PAGES IN THIS WEBSITE
5
Investments in shares: Directors' buying and selling
http://mythoughts-mohan.blogspot.com/2007/11/directors-buying-and-selling.html
Directors' buying and selling. Subscribe to: Post Comments (Atom). Links to my other blogs. Risks of investing in shares. Wait for the real bargain. Directors buying and selling. My capacity for risk is very high as I can afford to lose most of my capital without it affecting my lifestyle in any way. My attitude to risk is that I see no point in risking the money that I already have for more money that I will never need. View my complete profile.
Barclays PLC: November 2008
http://barclays-mohan.blogspot.com/2008_11_01_archive.html
My thoughts on Barclays as an investment. Tuesday, 4 November 2008. I decided to hold because I estimate that the yield (at the present price) will be 11% in 2010 and can be expected to increase in future years (till their next bout of excess risk taking and value destruction! My calculation is shown in the spreadsheet below. It includes the following assumptions:. 1 The profit after tax in 2010 will be the same as in 2007. 2 The tax rate will be unchanged. 4 Dividend will be 50% of eps. 1 Not lending to...
Barclays PLC: January 2008
http://barclays-mohan.blogspot.com/2008_01_01_archive.html
My thoughts on Barclays as an investment. Friday, 25 January 2008. Optimism from Bob Diamond. Extracts from Reuters 25 Jan 08. DAVOS, Switzerland (Reuters) - Barclays sees tougher market conditions in the next year as an opportunity for its investment banking arm to grow and invest, particularly in the United States, the bank's president said. Announcing a writedown of $2.7 billion (1.4 billion pounds) in November for losses on securities linked to the subprime crisis. We've seen the worst. We are bo...
Barclays PLC: September 2008
http://barclays-mohan.blogspot.com/2008_09_01_archive.html
My thoughts on Barclays as an investment. Sunday, 21 September 2008. Media comments re Lehman acquisition. Http:/ www.investorrelations.barclays.co.uk/INV/A/Content/Files/Lehman Press Release 170908.pdf. Barclays will acquire trading assets with a current estimated value of £40bn (US$72bn) and trading liabilities with a current estimated value of £38bn (US$68bn) for a cash consideration of £0.14bn (US$0.25bn). Barclays will also acquire the New York. Most of the price tag was accounted for by Lehman's Ne...
Barclays PLC: November 2007
http://barclays-mohan.blogspot.com/2007_11_01_archive.html
My thoughts on Barclays as an investment. Wednesday, 28 November 2007. Extracts below. Click on links for full articles. FT - Chris Hughes. Http:/ www.ft.com/cms/s/0/10771374-9d2a-11dc-af03-0000779fd2ac.html. John Varley needs the bank's non-investment banking business to step up a gear if he is to address Barclays' embarrassingly low stock market valuation. Moreover, income growth is strong in Barclays' international banking and wealth management businesses. The same goes for the BGI fund management...
Barclays PLC: February 2008
http://barclays-mohan.blogspot.com/2008_02_01_archive.html
My thoughts on Barclays as an investment. Tuesday, 19 February 2008. Press extracts, etc following prelims. Http:/ www.investorrelations.barclays.co.uk/INV/A/Content/Files/2007 Barclays Results Announcement web.pdf. Archived webcast of presentation following announcement at. Http:/ pres.investorrelations.barclays.co.uk/barclays059/default3.asp? Webcast of interview with John Varley at. Http:/ w3.cantos.com/cantos/dyn/org.php. Log in and search for "Barclays" in "Banks"). FT - Maggie Urry. Tier 1 capital ...
Barclays PLC: May 2009
http://barclays-mohan.blogspot.com/2009_05_01_archive.html
My thoughts on Barclays as an investment. Monday, 4 May 2009. Nassim Taleb has written two very enjoyable books so far. In his book "The Black Swan", he vividly exposed the risk of investing in banks:. I read this book in 2007 but did not heed its warning. These "highly improbable" banking disasters seem to be occurring rather frequently in recent decades. With banks so highly leveraged, I suppose this is to be be expected. Subscribe to: Posts (Atom). Links to my other blogs. My capacity for risk is very...
Barclays PLC: April 2008
http://barclays-mohan.blogspot.com/2008_04_01_archive.html
My thoughts on Barclays as an investment. Thursday, 24 April 2008. Barcap continues to expand. Extract from The independent on 25 April by Sean Farrell, Financial Editor. Http:/ www.independent.co.uk/news/business/news/barclays-rubbishes-rumours-of-rbsstyle-rights-issue-815502.html. Extracts from Bloomberg article on 22 April. Http:/ www.bloomberg.com/apps/news? Barclays Hires Archibald Cox Jr. as Americas Chairman (Update2). Barclays Plc . hired Archibald Cox Jr . The No. 1 priority for us is the U&...
Barclays PLC: January 2009
http://barclays-mohan.blogspot.com/2009_01_01_archive.html
My thoughts on Barclays as an investment. Friday, 23 January 2009. To trust the management or the markets? If the management is to be believed, the Barclays share price of about 50p now is very low. Is the market right in not trusting the management? Only time will tell. For the record, I give below some of the comments by management recently. It will be interesting to look at these a year or so from now. John Varley's interview on 22 Jan 09 at Cantos. Our predisposition would be to pay in cash. Accordi...
Investments in shares: Management
http://mythoughts-mohan.blogspot.com/2007/11/management.html
The quality of management is one of three key evaluations that an investor has to make. This is extremely difficult to do. And even if you do find a company which you think has outstanding management, ensure that it also satisfies the other two evaluations of economics of the business and valuation of the shares. Stephen Lofthouse discusses the problem of trying to select bargains based on insights into the quality of management:. Third, what is good management, and who would recognise it? Unless such a ...
TOTAL LINKS TO THIS WEBSITE
35
glaxman009
Thursday, November 29, 2007. There once was a man named steve Mcqueen he was the type of guy that would have his dog shit on peoples lawns but most of all this one policemans lawn. The reason for this was that along time ago steve was at the grand canyon with his dog. all of a sudden this police man walkes over and bumps into his dog knocking the poor dog into the depths of the canyon. The dog was never seen again. This is what started steves dislike for cops. He was the kind of guy. At once he would dri...
Glaxm Infotech
Highly Adaptable,Enterprise Class Application. GLAXM - HOSPITAL ERP. Avoid High Cost of Complexity. Glaxm Infotech was founded with a passion for challenging and redefining the 'boundaries of the possible'. Glaxm Infotech was founded with a passion for challenging and redefining the 'boundaries of the possible'. Glaxm delivers a broad and rich set of integrated business functionality on a global-ready platforms. The module structure is designed to offer scalability with the enterprise version offering un...
Their Profile - glaxmul - Skyrock.com
The position of the blocks have been saved. Did you like this profile? Mon, November 14, 2016. Here for: To hook up. My star sign : Capricorn. Post to my blog. Here you are free.
GlaxoSmithKline
My thoughts on GlaxoSmithKline as an investment. GSK is a good company operating in an industry whose fundamentals have deteriorated since the high growth era that ended a few years ago. To quote Warren Buffet: "When a management with a reputation for brilliance tackles a business with a reputation for poor fundamental economics, it is the reputation of the business that remains intact.". Subscribe to: Posts (Atom). Links to my other blogs. View my complete profile.
Glaxo Whistleblower Case - Record-setting settlement
Off-label marketing and kickbacks settlement. About Phillips & Cohen. Pfizer’s $2.3B settlement. Whistleblowers had big role in Glaxo’s record-setting settlement. A major component of GlaxoSmithKline record-setting settlement announced July 1, 2012, was Phillips and Cohen’s qui tam case, filed in Boston, Massachusetts, in 2003. The allegations regarding Glaxo’s off-label marketing of Advair to treat mild asthma, made in Phillips & Cohen’s lawsuit, settled for $686 million alone. Doctors may prescribe for...
Glaxo Whistleblower Case - Record-setting settlement
Off-label marketing and kickbacks settlement. About Phillips & Cohen. Pfizer’s $2.3B settlement. Whistleblowers had big role in Glaxo’s record-setting settlement. A major component of GlaxoSmithKline record-setting settlement announced July 1, 2012, was Phillips and Cohen’s qui tam case, filed in Boston, Massachusetts, in 2003. The allegations regarding Glaxo’s off-label marketing of Advair to treat mild asthma, made in Phillips & Cohen’s lawsuit, settled for $686 million alone. Doctors may prescribe for...
Glaxo Whistleblower Case - Record-setting settlement
Off-label marketing and kickbacks settlement. About Phillips & Cohen. Pfizer’s $2.3B settlement. Whistleblowers had big role in Glaxo’s record-setting settlement. A major component of GlaxoSmithKline record-setting settlement announced July 1, 2012, was Phillips and Cohen’s qui tam case, filed in Boston, Massachusetts, in 2003. The allegations regarding Glaxo’s off-label marketing of Advair to treat mild asthma, made in Phillips & Cohen’s lawsuit, settled for $686 million alone. Doctors may prescribe for...
glaxo-smithkline.com
The Sponsored Listings displayed above are served automatically by a third party. Neither the service provider nor the domain owner maintain any relationship with the advertisers. In case of trademark issues please contact the domain owner directly (contact information can be found in whois).
Glaxo Whistleblower Case - Record-setting settlement
Off-label marketing and kickbacks settlement. About Phillips & Cohen. Pfizer’s $2.3B settlement. Whistleblowers had big role in Glaxo’s record-setting settlement. A major component of GlaxoSmithKline record-setting settlement announced July 1, 2012, was Phillips and Cohen’s qui tam case, filed in Boston, Massachusetts, in 2003. The allegations regarding Glaxo’s off-label marketing of Advair to treat mild asthma, made in Phillips & Cohen’s lawsuit, settled for $686 million alone. Doctors may prescribe for...
